The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of myelodysplastic syndromes: an evidence-based review.
Clinical research examining the role of hematopoietic stem cell transplantation (SCT) in the therapy of myelodysplastic syndromes (MDS) in adults is presented and critically evaluated in this systematic evidence-based review. Specific criteria were used for searching the published literature and for grading the quality and strength of the evidence and the strength of the treatment recommendations. Treatment recommendations based on the evidence are presented in Table 3, and were reached unanimously by a panel of MDS experts. The identified priority areas of needed future research in MDS include: (1) the benefit of using alternative donor sources (eg, cord blood; haploidentical family donors) for patients without matched sibling or unrelated donors; (2) the role and appropriate timing of allogeneic SCT in combination with hypomethylating and immunomodulatory treatment regimens; (3) randomized trials comparing the safety and efficacy of various novel agents for treating MDS; and (4) the influence of the various MDS treatment modalities on patient-reported quality-of-life outcomes.
Oliansky
Denise M
DM
Roswell Park Cancer Institute, Buffalo, New York 14263, USA.
Antin
Joseph H
JH
Bennett
John M
JM
Deeg
H Joachim
HJ
Engelhardt
Christin
C
Heptinstall
Kathleen V
KV
de Lima
Marcos
M
Gore
Steven D
SD
Potts
Ronald G
RG
Silverman
Lewis R
LR
Jones
Roy B
RB
McCarthy
Philip L
PL
Hahn
Theresa
T
D000970:Antineoplastic Agents / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D019317:Evidence-Based Medicine; D018380:Hematopoietic Stem Cell Transplantation / Q000379:methods*; D006801:Humans; D015201:Meta-Analysis as Topic; D009190:Myelodysplastic Syndromes / Q000175:diagnosis / Q000188:drug therapy / Q000628:therapy*; D011379:Prognosis; D012720:Severity of Illness Index
D000970:Antineoplastic Agents